Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi, L Køber… - European heart …, 2020 - academic.oup.com
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi… - European Heart …, 2020 - research.regionh.dk
AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi… - European heart …, 2020 - pubmed.ncbi.nlm.nih.gov
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi, L Køber… - European Heart …, 2020 - eprints.gla.ac.uk
Aims: Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
[HTML][HTML] Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi, L Køber… - European Heart …, 2020 - ncbi.nlm.nih.gov
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
[引用][C] Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Boehm, SE Inzucchi, L Kober… - European Heart …, 2020 - hero.epa.gov
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and
Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) | Health & Environmental …
Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) | Health & Environmental …
[PDF][PDF] Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi, L Køber… - European Heart …, 2020 - academic.oup.com
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
M Serenelli, M Böhm, SE Inzucchi… - European Heart …, 2020 - search.ebscohost.com
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi, L Køber… - European Heart …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Aims</jats: title>< jats: p>
Concern about hypotension often leads to withholding of beneficial therapy in patients with …
Concern about hypotension often leads to withholding of beneficial therapy in patients with …
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
M Serenelli, M Böhm, SE Inzucchi, L Køber… - European Heart …, 2020 - europepmc.org
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …